Proteomic analyses in aggressive MF demonstrated that PARP-1 was overexpressed in patients with early-stage MF and may serve not only as a biomarker at initial biopsy for a disease that may become aggressive but also as a new therapeutic target for advanced MF(Lemchak et al., 2018). This evidence concerns the gene PARP1 and mycosis fungoides.